CVM Stock Summary and Trading Ideas (Cel-Sci | AMEX:CVM)

CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.

Cel-Sci trades on the AMEX stock market under the symbol CVM.

As of September 25, 2026, CVM stock price declined to $1.67 with 35,969 million shares trading.

CVM has a beta of 3.08, meaning it tends to be more sensitive to market movements. CVM has a correlation of 0.12 to the broad based SPY ETF.

CVM has a market cap of $29.37 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, CVM traded as high as $96.90 and as low as $.89.

The top ETF exchange traded funds that CVM belongs to (by Net Assets): VTI, VXF, BUSM.

CVM has underperformed the market in the last year with a return of -80.4%, while SPY returned +18.4%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in CVM shares. However, CVM has outperformed the market in the last 3 month and 2 week periods, returning +71.4% and +12.1%, while SPY returned +5.3% and +1.2%, respectively. This indicates CVM has been having a stronger performance recently.

CVM support price is $1.65 and resistance is $1.79 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CVM shares will trade within this expected range on the day.